Maya Kayouka1, Pascal Houzé2,3, Marc Lejay4, Frederic J Baud4,5, Kamil Kuca6. 1. Bioactive Molecules Research Laboratory, Faculty of Sciences, Section II, Lebanese University, Beirut, Lebanon. 2. Laboratoire de Toxicologie Biologique, GH Lariboisière-St Louis-F. Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), 75010 Paris, France. 3. Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR8258-U1022, Faculté de Pharmacie Paris Descartes, Université de Paris, 75006 Paris, France. 4. Département d'Anesthésie-Réanimation-SAMU de Paris, Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France. 5. EA 7323, Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Université de Paris, F-75006 Paris, France. 6. Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove 50003, Czech Republic.
Abstract
BACKGROUND: Oximes are used in addition to atropine to treat organophosphate poisoning. However, the efficiency of oximes is still a matter of debate. In vitro experiments suggested than new oximes are more potent than the commercial oximes. However, the antidotal activity of new oximes has not been assessed in vivo. METHODS: The aim of this work was to assess the safety and efficiency of new oximes compared to pralidoxime in a rat model of diethyl paraoxon-induced non-lethal respiratory toxicity. RESULTS: Safety study of oximes showed no adverse effects on ventilation in rats. KO-33, KO-48, KO-74 oximes did not exhibit significant antidotal effect in vivo. In contrast, KO-27 and BI-6 showed evidence of antidotal activity by normalization of respiratory frequency and respiratory times. KO-27 became inefficient only during the last 30 min of the study. In contrast, pralidoxime demonstrated to be inefficient at 30 min post injection. Inversely, the antidotal activity of BI-6 occurred lately, within the last 90 min post injection. CONCLUSION: This study showed respiratory safety of new oximes. Regarding, the efficiency, KO-27 revealed to be a rapid acting antidote toward diethylparaoxon-induced respiratory toxicity, meanwhile BI-6 was a late-acting antidote. Simultaneous administration of these two oximes might result in a complete and prolonged antidotal efficiency.
BACKGROUND:Oximes are used in addition to atropine to treat organophosphatepoisoning. However, the efficiency of oximes is still a matter of debate. In vitro experiments suggested than new oximes are more potent than the commercial oximes. However, the antidotal activity of new oximes has not been assessed in vivo. METHODS: The aim of this work was to assess the safety and efficiency of new oximes compared to pralidoxime in a rat model of diethyl paraoxon-induced non-lethal respiratory toxicity. RESULTS: Safety study of oximes showed no adverse effects on ventilation in rats. KO-33, KO-48, KO-74 oximes did not exhibit significant antidotal effect in vivo. In contrast, KO-27 and BI-6 showed evidence of antidotal activity by normalization of respiratory frequency and respiratory times. KO-27 became inefficient only during the last 30 min of the study. In contrast, pralidoxime demonstrated to be inefficient at 30 min post injection. Inversely, the antidotal activity of BI-6 occurred lately, within the last 90 min post injection. CONCLUSION: This study showed respiratory safety of new oximes. Regarding, the efficiency, KO-27 revealed to be a rapid acting antidote toward diethylparaoxon-induced respiratory toxicity, meanwhile BI-6 was a late-acting antidote. Simultaneous administration of these two oximes might result in a complete and prolonged antidotal efficiency.
Authors: Dietrich E Lorke; Syed M Nurulain; Mohamed Y Hasan; Kamil Kuča; Georg A Petroianu Journal: Int J Mol Sci Date: 2021-03-17 Impact factor: 5.923